Volume | 1,144,903 |
|
|||||
News | - | ||||||
Day High | 71.855 | Low High |
|||||
Day Low | 69.96 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Cytokinetics Inc | CYTK | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
71.41 | 69.96 | 71.855 | 71.41 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
16,922 | 1,144,903 | $ 70.93 | $ 81,202,670 | - | 25.98 - 110.25 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
15:43:52 | 20 | $ 70.6109 | USD |
Cytokinetics (CYTK) Options Flow Summary
Cytokinetics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
7.25B | 103.00M | - | 7.53M | -526.24M | -5.11 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Cytokinetics News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical CYTK Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 67.90 | 74.6799 | 65.13 | 69.74 | 2,093,742 | 2.66 | 3.92% |
1 Month | 73.86 | 75.03 | 61.33 | 66.63 | 3,147,155 | -3.30 | -4.47% |
3 Months | 87.00 | 110.25 | 61.33 | 81.45 | 3,514,647 | -16.44 | -18.90% |
6 Months | 29.81 | 110.25 | 25.98 | 66.76 | 2,930,274 | 40.75 | 136.70% |
1 Year | 34.36 | 110.25 | 25.98 | 59.59 | 1,880,953 | 36.20 | 105.36% |
3 Years | 23.69 | 110.25 | 17.72 | 47.28 | 1,390,029 | 46.87 | 197.85% |
5 Years | 8.24 | 110.25 | 7.01 | 38.20 | 1,179,926 | 62.32 | 756.31% |
Cytokinetics Description
Cytokinetics Inc is a biotechnology company that develops muscle biology-driven treatments for diseases characterized by reduced muscle function, muscle weakness, and fatigue. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. |